McGraw-Hill’s 2022/2023 Top 300 Pharmacy Drug Cards

Download this app from:

The quickest, most efficient way for mastering critical facts about common drugs

Perfect for NAPLEX and course review, McGraw Hill’s 2022-2023 Top 300 Pharmacy Drug Cards is the most concise and up-to-date resource for building a solid knowledge base of the most commonly used drugs.

Each card includes:
• Generic and common name
• Dosage Forms
• Approved Dose and Indications
• Off-Label Use
• Contraindications
• Adverse Reactions
• Drug Interactions
• Monitoring Parameters
• Medication Safety Issues and Black Box Warnings
• Strong focus on patient safety

Adverse reactions are organized by common, less common, and rare but serious to help you organize your thoughts for counseling patients

No internet connection needed to view the full app. It is all ready for super quick image and information retrieval. This app is optimized for whatever size device you are using, either phone or tablet.

Each card also features a photograph as well as important drug information. You can also search the entire text with our lightning fast search tool. The search tool shows you suggested words as you type so it is quick and helps with spelling issues. You can also add notes to each drug card, as well as bookmark drug cards as Know and Don’t Know to help with studying. You also have the ability to change the text size for easier reading.

This interactive app is based on the full content of McGraw-Hill’s 2022/2023 Top 300 Pharmacy Drug Cards.
ISBN-13: 978-1260467345
ISBN-10: 1260467341

Jill M. Kolesar, PharmD, MS, BCPS, FCCP
University Research Professor, Colleges of Pharmacy and Medicine
Director, Precision Medicine Initiatives
Markey Cancer Center
University of Kentucky
Lexington, Kentucky

Lee C. Vermeulen, BSPharm, MS, FCCP, FFIP
Chief Efficiency Officer
UK HealthCare
Professor of Medicine and Pharmacy
University of Kentucky
Lexington, Kentucky

Disclaimer: This app is intended for the education of healthcare professionals and not as a diagnostic and treatment reference for the general population.

Developed by Usatine Media, LLC
Richard P. Usatine, MD, Co-President, Professor of Family & Community Medicine, Professor of Dermatology and Cutaneous Surgery, University of Texas Health Science Center San Antonio
Peter Erickson, Co-President, Lead Software Developer